ReviewBiomedicines2017
The Role of Angiogenesis in Cancer Treatment.
Review in Biomedicines, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 295 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
295 citing papers in PubMed.
- Rh-Endostatin Plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study.The oncologist · 2022Trial
- Evaluating the Anticancer and Anti-Angiogenic Efficacy of Bergaptol in 2D and 3D Tumor Microtissue Models.Chemistry & biodiversity · 2026Article
- Extracellular Vesicles as Immunomodulatory Mediators in Angiogenic-Osteogenic Coupling: Mechanistic Insights and Therapeutic Potential.Advanced healthcare materials · 2026Review
- Microglia-Mediated Vascular Network Remodeling After Ischemic Stroke: An Immunovascular Repair Framework.Cells · 2026Review
- The role of extracellular vesicles-associated proteins markers in prostate cancer: a review.Discover oncology · 2026Review
- Therapeutic profiling of dihydroartemisinin using in vitro and in vivo models reveals anti-glioma potential.Cancer cell international · 2026Article
- Silencing progestagen-associated endometrial protein (PAEP) suppresses sorafenib resistance and enhances sorafenib-induced ferroptosis in hepatocellular carcinoma.Liver research (Beijing, China) · 2026Article
- Radiosensitizing effects of silver nanoparticles targeting angiogenesis and matrix metalloproteinase signaling in triple negative breast cancer cell lines.Scientific reports · 2026Article
- Huayu Wan enhances immune checkpoint inhibitor efficacy in triple-negative breast cancer by normalizing tumor vasculature and remodeling the tumor immune microenvironment.Frontiers in immunology · 2026Article
- The Role of Angiogenesis in Breast Cancer and Obesity: Unravelling the Connection.International journal of breast cancer · 2026Review
- Ubiquitin-conjugating Enzymes in Cancer.International journal of biological sciences · 2026Review
- Microenvironmental and Molecular Pathways Driving Dormancy Escape in Bone Metastases.International journal of molecular sciences · 2025Review
- Article
- Ketoboronate as a Minimal Covalent-Reversible Tag for Targeted Lysosomal Degradation of Extracellular and Membrane Proteins.Journal of the American Chemical Society · 2025Article
- Article
- A Protocol for the In Vitro Culturing of Vascularized Pancreatic Islet Organoids.Bioengineering (Basel, Switzerland) · 2025Article
- Exploration of the Mechanism ofACS omega · 2025Article
- The polyphenolic compound, α-conidendrin, exerts anti-colon cancer and anti-angiogenic effects by targeting several signaling molecules.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Potential role of thymoquinone to treat gastrointestinal cancers: insights into its molecular mechanisms.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Nature-Inspired Strategies in Cancer Management: The Potential of Plant Extracts in Modulating Tumour Biology.International journal of molecular sciences · 2025Review
235 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of anti-angiogenesis drugs have been FDA-approved and are being used in cancer treatment, and a number of other agents are in different stages of clinical development or in preclinical evaluation. However, pharmacologic anti-angiogenesis strategies that arrest tumor progression might not be enough to eradicate tumors. Decreased anti-angiogenesis activity in single mechanism-based anti-angiogenic strategies is due to the redundancy, multiplicity, and development of compensatory mechanism by which blood vessels are remodeled. Improving anti-angiogenesis drug efficacy will require identification of broad-spectrum anti-angiogenesis targets. These strategies may have novel features, such as increased porosity, and are the result of complex interactions among endothelial cells, extracellular matrix proteins, growth factors, pericyte, and smooth muscle cells. Thus, combinations of anti-angiogenic drugs and other anticancer strategies such as chemotherapy appear essential for optimal outcome in cancer patients. This review will focus on the role of anti-angiogenesis strategies in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.